Back to Search
Start Over
Pegylated liposomal doxorubicin: Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (Review)
- Source :
- ResearcherID, Scopus-Elsevier, Europe PubMed Central
- Publication Year :
- 2004
- Publisher :
- Spandidos Publications, 2004.
-
Abstract
- Anthracyclines are among the most active antineoplastic drugs developed to date, used both in the treatment of solid cancers, such as breast and ovarian cancer and sarcomas, and of hematologic cancers. However, their clinical use is limited by cardiotoxicity, which is observed at a range of 0.4-41\%. The risk of this side effect can be minimized by using cardioprotective agents, planning dosing schedules to lower the anthracycline peak plasma concentration, identifying and monitoring high-risk patients, keeping in mind that early anthracycline-induced histologic changes may be identified successfully by cardiac biopsy. Nonetheless, the challenge to increase the tumor response to chemotherapy while keeping low the cardiac risk may be now met by the use of a recently introduced polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD). Here, we review the pharmacologic properties of PLD as well as the results of phases I, II and III trials demonstrating activity and low cardiac toxicity associated with the use of this novel drug.
- Subjects :
- Drug
Cancer Research
Side effect
Anthracycline
medicine.medical_treatment
media_common.quotation_subject
Pharmacology
doxorubicin
Polyethylene Glycols
Risk Factors
Neoplasms
Humans
Medicine
Anthracyclines
Doxorubicin
media_common
Clinical Trials as Topic
Chemotherapy
Cardiotoxicity
Antibiotics, Antineoplastic
business.industry
toxicity
Cancer
Drug Synergism
Heart
General Medicine
medicine.disease
Treatment Outcome
Oncology
Liposomes
liposome
business
Ovarian cancer
medicine.drug
Subjects
Details
- ISSN :
- 17912431 and 1021335X
- Database :
- OpenAIRE
- Journal :
- Oncology Reports
- Accession number :
- edsair.doi.dedup.....90b8ef58811ffe6fa8108e41ca43ff25